GoAI
Get started
Inhibrx Biosciences Inc. logo

Inhibrx Biosciences Inc.

INBX

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$103.63

+$4.48 · +4.52%

Aug 21, 4:00 PM ET

INBX company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

2

Overpriced

Momentum

53

Neutral

Sentiment

61

Bullish

Risk resilience

19

Extreme Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Mark Lappe
Listed since
May 29, 2024
Employees
110

Market position

Day range

Current $103.63

52-week range

Current $103.63

Open
$100.76
Previous close
$99.15
Volume
220.74K
0.55× average
Average volume
398.48K
Average daily volume
Market cap
1.52B USD
Beta
3.52
Market reference 1
50-day average
$91.5159
+13.24% above average
200-day average
$86.7989
+19.39% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
-11.67×
P/B (TTM)
-30.65×
P/S (TTM)
0×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%

Financial health

Debt / equity
-0.1×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends944737%540933%137129%-266675%Gross margin, FY2021: 100.00%Gross margin, FY2022: -4926.73%Gross margin, FY2023: 33.83%Gross margin, FY2024: -1042.50%Gross margin, FY2025: -91.00%Operating margin, FY2021: -1058.83%Operating margin, FY2022: -5890.37%Operating margin, FY2023: -12178.94%Operating margin, FY2024: -165724.00%Operating margin, FY2025: -10386.54%Net margin, FY2021: -1130.80%Net margin, FY2022: -6625.27%Net margin, FY2023: -13408.94%Net margin, FY2024: 843786.00%Net margin, FY2025: -10773.46%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 100.00%. Gross margin FY2022 -4926.73%. Gross margin FY2023 33.83%. Gross margin FY2024 -1042.50%. Gross margin FY2025 -91.00%. Operating margin FY2021 -1058.83%. Operating margin FY2022 -5890.37%. Operating margin FY2023 -12178.94%. Operating margin FY2024 -165724.00%. Operating margin FY2025 -10386.54%. Net margin FY2021 -1130.80%. Net margin FY2022 -6625.27%. Net margin FY2023 -13408.94%. Net margin FY2024 843786.00%. Net margin FY2025 -10773.46%.

Income trends

Revenue

1.3M USD+550.00%

Operating income

−135.03M USD+59.26%

Net income

−140.06M USD−1.83B USD
Income trends across reported periods1.89B USD1.08B USD274.26M USD−533.35M USDRevenue, FY2021: 7.23M USDRevenue, FY2022: 2.19M USDRevenue, FY2023: 1.8M USDRevenue, FY2024: 200K USDRevenue, FY2025: 1.3M USDOperating income, FY2021: −76.56M USDOperating income, FY2022: −129.12M USDOperating income, FY2023: −219.22M USDOperating income, FY2024: −331.45M USDOperating income, FY2025: −135.03M USDNet income, FY2021: −81.77M USDNet income, FY2022: −145.23M USDNet income, FY2023: −241.36M USDNet income, FY2024: 1.69B USDNet income, FY2025: −140.06M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 7.23M USD. Revenue FY2022 2.19M USD. Revenue FY2023 1.8M USD. Revenue FY2024 200K USD. Revenue FY2025 1.3M USD. Operating income FY2021 −76.56M USD. Operating income FY2022 −129.12M USD. Operating income FY2023 −219.22M USD. Operating income FY2024 −331.45M USD. Operating income FY2025 −135.03M USD. Net income FY2021 −81.77M USD. Net income FY2022 −145.23M USD. Net income FY2023 −241.36M USD. Net income FY2024 1.69B USD. Net income FY2025 −140.06M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue1.3M USD200K USD1.8M USD2.19M USD7.23M USD
Cost of goods sold2.48M USD2.29M USD1.19M USD110.19M USD—
Gross profit−1.18M USD−2.09M USD609K USD−107.99M USD7.23M USD
Research and development113.03M USD203.74M USD190.65M USD110.19M USD71.44M USD
Selling, general, and administrative23.3M USD127.91M USD29.38M USD21.12M USD12.36M USD
Operating expenses133.84M USD329.36M USD219.83M USD21.12M USD83.8M USD
Interest income7.55M USD10.94M USD11.92M USD16.11M USD—
Interest expense12.2M USD13.49M USD31.84M USD16.11M USD5.22M USD
Depreciation and amortization2.48M USD2.29M USD1.19M USD1.23M USD—
Operating income−135.03M USD−331.45M USD−219.22M USD−129.12M USD−76.56M USD
Net income−140.06M USD1.69B USD−241.36M USD−145.23M USD−81.77M USD

Company facts updated Aug 24, 2026.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$325

213.62% upside
Past 12 months12-month forecastHigh $325Average $325Low $325

INBX news

prnewswire.com

Inhibrx Reports Second Quarter 2026 Financial Results

SAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the second quarter of 2026. The biopharmaceutical company has two…

Read source
seekingalpha.com

Inhibrx Biosciences: The Rare Disease Launch Is Only The Opening Act

Inhibrx is transitioning from a platform to a clinical-stage biotech, with ozekibart and INBRX-106 as key value drivers. Ozekibart's BLA for chondrosarcoma is under FDA review with an April 14, 2027 PDUFA date, supported…

Read source
prnewswire.com

Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million

SAN DIEGO, July 16, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. ("Inhibrx" or the "Company") (Nasdaq: INBX), a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates,…

Read source
zacks.com

Are You Looking for a Top Momentum Pick? Why Inhibrx Biosciences, Inc. (INBX) is a Great Choice

Does Inhibrx Biosciences, Inc. (INBX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Read source
prnewswire.com

Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma

No filing review issues identified by FDA with PDUFA goal date set for April 14, 2027 If Approved, Ozekibart Would Be the First and Only FDA-Approved Treatment for Unresectable or Metastatic Conventional Chondrosarcoma…

Read source

Corporate actions

Corporate action history

Dividend

Ex-dividend May 30, 2024

$0.85

Irregular

Record May 30, 2024 · Payment Jun 20, 2024

INBX peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding INBX

Funds reporting this stock among their holdings, ordered by reported position size.

State Street SPDR S&P Biotech ETF logoState Street SPDR S&P Biotech ETFXBI
Market value
41.74M
Weight
0.37%
AUM
11.39B USD
Expense ratio
0.35%
Price / 1D
$165.73+1.44%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
30.33M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
24.13M
Weight
0.03%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
9.12M
Weight
0.01%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Biotechnology ETF logoiShares Biotechnology ETFIBB
Market value
8.1M
Weight
0.08%
AUM
10.75B USD
Expense ratio
0.44%
Price / 1D
$213.56+1.29%
First Trust Small Cap Growth AlphaDEX Fund logoFirst Trust Small Cap Growth AlphaDEX FundFYC
Market value
7.82M
Weight
0.55%
AUM
1.42B USD
Expense ratio
0.70%
Price / 1D
$122+0.71%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
7.15M
Weight
0.05%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
4.37M
Weight
0.02%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%

Continue in GoAI

Research INBX

research.disclaimer